Vladimir Stepanov

Background/Objectives: Leucine-rich repeat kinase 2 (LRRK2) is an enzyme implicated in Parkinson’s disease (PD) and a potential therapeutic target. LRRK2 PET radioligands could therefore function as imaging biomarkers for PD and as tools to measure enzyme occupancy of novel therapeutic candidates. This study aimed at developing novel radioligands for imaging using positron emission tomography (PET). Specific objectives were to synthesize fluorine-18-labeled pyrrolopyridine 1 ([¹⁸F]1), pyrrolo-pyrimidine 2 ([¹⁸F]2), as well as carbon-11-labeled pyrrolo-pyrimidine 3 ([¹¹C]3), and examine their binding specificity, using in vitro autoradiography (ARG) and in vivo positron emission tomography (PET) imaging in non-human primates (NHPs). Methods: Radiolabeling was achieved either by classical one-step fluorine-18 nucleophilic substitution reaction or by methylation using carbon-11 methane. [¹⁸F]1 and [¹⁸F]2 were tested in NHP and human whole-hemisphere ARG experiments. PET imaging was performed in cynomolgus monkeys. Radiometabolites were measured in monkey plasma using gradient HPLC. Results: The results demonstrated successful radiolabeling of all three ligands. In ARG studies, both [¹⁸F]1 and [¹⁸F]2 displayed binding in brain slices from NHP and human samples. The binding of [¹⁸F]1 was blocked by cold Compound 1 and structurally distinct Compound 3, but not by the structurally distinct LRRK2 inhibitor PFE-360. On the other hand, the binding of [¹⁸F]2 was blocked by PFE-360 in certain regions of the brain, indicating some level of specific binding to LRRK2. All three ligands showed relevant brain uptake (>3%ID), with highest uptake being observed for [¹⁸F]1, particularly in the thalamus. In contrast, brain uptake of [¹⁸F]2 and [¹¹C]3 was evenly distributed across all brain regions. No blocking effect of [¹⁸F]1 was observed after pretreatment with the structurally distinct LRRK2 inhibitors PFE-360 (0.5 mg/kg, iv) and GEN-7915 (40 mg/kg). Conclusions: PET imaging indicated a low in vivo specific binding of the radioligands in the cynomolgus monkey brain, suggesting that the radioligands are not suitable for LRRK2 imaging in vivo with PET. This study emphasizes the challenges in the development of PET radioligands for imaging LRRK2 and the need for additional work to achieve this goal.

Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Our aim was to label a series of structurally related PDE10A inhibitors with carbon‐11 and evaluate them as potential positron emission tomography (PET) radioligands for PDE10A using nonhuman primates. The series consisted of seven compounds based on the 3‐(1H‐pyrazol‐5‐yl)pyridazin‐4(1H)‐one backbone. These compounds were selected from the initial larger library based on a number of parameters such as affinity, selectivity for hPDE10A in in vitro tests, lipophilicity, and on the results of multidrug resistance protein 1 (MDR1)‐LLCPK1 and the parallel artificial membrane permeability assays. Seven radioligands (KIT‐1, 3, 5, 6, 7, 9, and 12) were radiolabeled with carbon‐11 employing O‐methylation on the hydroxyl moiety using [¹¹C]methyl triflate. In vivo examination of each radioligand was performed using PET in rhesus monkeys; analysis of radiometabolites in plasma also was conducted using HPLC. All seven radioligands were labeled with high (>90%) incorporation of [¹¹C]methyl triflate into their appropriate precursors and with high specific radioactivity. Carbon‐11 labeled KIT‐5 and KIT‐6 showed high accumulation in the striatum, consistent with the known anatomical distribution of PDE10A in brain, accompanied by fast washout and high specific binding ratio. In particular [¹¹C]KIT‐6, named [¹¹C]T‐773, is a promising PET tool for further examination of PDE10A in human brain.

[¹¹C]T-773 is a new radioligand for positron emission tomography (PET) targeting the phosphodiesterase 10A enzyme (PDE10A). PDE10A is highly expressed in the striatum by medium spiny neurons, and it has been demonstrated to be involved in the regulation of striatal signaling through the reduction of medium spiny neuronal sensitivity towards glutamatergic excitation. PDE10A is associated with Parkinson’s disease and different neuropsychiatric disorders such as Huntington’s disease, obsessive-compulsive disorders (OCD) and schizophrenia. Studies have indicated that the inhibition of PDE10A may represent a novel therapeutic approach to the treatment of the aforementioned diseases characterized by the reduced activity of medium spiny neurons. An appropriate PET radioligand for PDE10A would help to facilitate drug development and drug evaluation. We have evaluated the [¹¹C]T-773 ligand in PDE10A knockout mice (heterozygous [HET] and homozygous [HOM]) as well as in normal control animals (WILD) with PET. The regional percent standardized uptake values (%SUV; mean ± SD) in the striatum were 48.2 ± 1.0 (HOM), 63.6 ± 5.3 (HET) and 85.1 ± 6.3 (WILD). Between each animal group the striatal %SUV values were significantly different (p < 0.0001). The striatal BP_ND values (mean ± SD) were 0.0 ± 0.0 (HOM), 0.14 ± 0.07 (HET) and 0.56 ± 0.15 (WILD). The BP_ND values were significantly lower in homozygous and heterozygous animals compared to wild type (p < 0.0001). The novel PDE10A radioligand [¹¹C]T-773 shows increased signals with higher levels of PDE10A and acceptable binding in the striatum in control animals compared to knockout mice.

The aim of this study was to develop a direct fluorination method for the preparation of [¹⁸F]‐(E)‐N‐(3‐iodoprop‐2‐enyl)‐2β‐carbofluoroethoxy‐3β‐(4′‐methyl‐phenyl)nortropane ([¹⁸F]FE‐PE2I (VI). The synthesis procedure relies on the conventional Kryptofix‐mediated nucleophilic ¹⁸F‐substitution of the tosylate group in the precursor, TsOE‐PE2I (V). Out of reaction conditions tested, the highest fluorination efficiency was obtained in dimethyl sulfoxide at 140°C. The reaction mixture was purified by semi‐preparative HPLC, followed‐up by a standard Sep‐Pak SPE procedure. On average, 1.0 GBq of [¹⁸F]FE‐PE2I was produced from 5‐min irradiation at 35 μA (dimethyl sulfoxide, 5 min/140°C). Decay‐uncorrected yield of the product after HPLC purification and formulation was in the order of 20%. Specific radioactivity of [¹⁸F]FE‐PE2I at 15 min after EOS was 3.3–5.1 Ci/µmol (n = 3); radiochemical purity was >98% (n = 4). This direct nucleophilic fluorination strategy is well suited for the automation of the entire synthesis of [¹⁸F]FE‐PE2I in a modern PET synthesizer for human PET application. In addition, the ¹⁸F‐incorporation rate into TsOE‐PE2I was evaluated using radio‐thin layer chromatography (TLC) and radio‐HPLC. The suggested HPLC method (ACE 5 C18‐HL column and acetonitrile/0.1 M NH₄CO₂ (80:20)) was found to be suitable for evaluation of ‘free’ ¹⁸F‐fluoride in the reaction mixture; in addition, this method allowed the detection of three radiolabelled by‐products that were not discernable with the TLC approach. Therefore, we conclude that the HPLC approach may serve as a good alternative to traditional radio‐TLC technique as it provides more detailed information about the fluorination process in the reaction kinetics or optimization studies. Copyright © 2012 John Wiley & Sons, Ltd.